Is Vaginal Progesterone More Effective to Treat Threatened Preterm Labour than Oral Nifedipine?

Authors

  • Sajia Hafeez Woman Medical Officer Obs & Gynae Deptt. Buch Hospital,Multan
  • Bushra Khan Associate Professor Obs & Gynae deptt . Bakhtawar Amin Hospital,Multan
  • Maria Khan Assistant Professor obstetrics & Gynaecology Bakhtawar amin medical and dental college multan
  • Sadaf Zahra Syed Assistant Professor obstetrics &Gynaecology Fatima Jinnah Medical University/Sir Ganga Ram Hospital
  • Fatima Waheed Assistant Professor Obs and Gynae King Edward Medical University Lahore.
  • Rubina Mustafa Woman Medical Officer Lady Willingdon Hospital Lahore

DOI:

https://doi.org/10.48036/apims.v13i4.977

Keywords:

Tocolytic therapy, Nifedipine, Progesterone

Abstract

Objective: To compare the effectiveness of vaginal progesterone versus oral nifedipine in the treatment of threatened preterm labor (TPL).

Methodology: This randomized control trial was carried out at Gynae and OBS department of Ibn-E-Siena Hospital, Multan, during a period of six months from December 2020 to June 2021. Participants were randomly allocated to either the vaginal progesterone group or the oral nifedipine group using computer-generated randomization. In Group A, participants received oral nifedipine at a dose of 20mg every 30 minutes for three initial doses, followed by long-acting nifedipine SR 20mg every 12 hours until reaching 37 weeks of gestational age or until cervical dilation exceeded 4cm. In Group B, participants were instructed to use vaginal micronized progesterone tablets at a dosage of 200mg once daily until reaching 37 weeks of gestational age or until cervical dilation exceeded 4cm. Effectiveness, refers to the ability of each treatment option to successfully prolong pregnancy duration in cases of threatened preterm labor.

Results: The mean age of the subjects was 29.6 years, with a standard deviation of 5.44 years. Mean gestational age was 33.32 weeks. In Group A, oral nifedipine showed effectiveness in (73.0%) of the cases. Conversely, Group B, which received vaginal progesterone, exhibited significantly higher efficacy rates, among 57 (90.5%) of the patients (p-value of 0.011). Effectiveness among two treatment modalities was found to be statistically insignificant according to age and parity of the women (p=>0.05).

Conclusion: Study revealed a significant difference in efficacy between the two treatment modalities. Specifically, vaginal progesterone demonstrates superior efficacy compared to oral nifedipine, which underscores the potential advantages of vaginal progesterone in managing threatened preterm labor.

Downloads

Published

2024-01-09

Issue

Section

Original Articles